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L E T T E R  T O  T H E  E D I T O R
Acquired haemophilia A after alemtuzumab therapy
Treatment with alemtuzumab leads to a prolonged depletion of 
T- and B cells, natural killer cells, dendritic cells and monocytes.1 
Alemtuzumab therapy is associated with secondary auto-immune 
disorders, including auto-immune thyroid disease, immune throm-
bocytopenia and inflammatory neuropathy.1 Here, two patients with 
acquired haemophilia A (AHA) are described who were previously 
treated with alemtuzumab.
Patient 1 was a 24-year-old man who received a kidney transplant 
because of end-stage kidney disease caused by Alport syndrome. 
One year after transplantation, he was treated for a mixed-type 
kidney transplant rejection. He received methylprednisolone (total 
dose 3000 mg) and intravenous immunoglobulins (2 g/kg) followed 
by alemtuzumab (30 mg, subcutaneously on two consecutive days). 
Four years after treatment for rejection, he presented with spon-
taneous bruising. He did not experience unintentional weight loss, 
fever, infection or night sweats. His immunosuppressive regimen at 
that time consisted of tacrolimus and prednisolone (5 mg/d). Physical 
examination at presentation revealed multiple large haematomas on 
all extremities and on his thorax. Laboratory testing demonstrated 
an isolated prolonged activated partial thromboplastin time (aPTT) 
of 80 seconds (Table 1). The aPTT did not correct after mixing with 
normal pooled plasma (46 seconds). Factor VIII coagulation activ-
ity (FVIII:C) was strongly reduced (0.02 U/mL; normal 0.60-1.40 U/
mL). A factor VIII inhibitor was confirmed and quantified with the 
Nijmegen modification of the Bethesda assay (10 Bethesda Units 
[BU]/mL; Table 1 and Figure 1A). Additional workup showed re-
population of T- and B-lymphocytes (Table 1). The patient was di-
agnosed with AHA and was treated with a single administration of 
activated prothrombin complex concentrate (factor eight inhibitor 
bypassing activity [FEIBA®] 50 U/kg) to stop bleeding of a severe 
bleeding in his arm resulting in pain and impairment of joint mobility 
of the elbow (Figure 1A). Immunosuppressive therapy was immedi-
ately started with prednisolone (1 mg/kg/d, ie 80 mg/d) and cyclo-
phosphamide (100 mg/d). The aPTT shortened and FVIII:C increased 
within 2 weeks whereupon cyclophosphamide was discontinued 
(Figure 1A). The patient achieved complete remission of the AHA 
after 6 weeks with normalization of FVIII:C and no detectable factor 
VIII inhibitor (Figure 1A). Prednisolone was tapered to 5 mg over a 
period of 6 months. Thereafter, prednisolone was continued (5 mg/d) 
as immunosuppressive therapy for the kidney transplantation.
Patient 2 was a 42-year-old man who received alemtuzumab (in-
travenously, 12 mg/d for 5 days and 1 year later 12 mg/d for 3 days) 
for relapsing-remitting multiple sclerosis.2 Fourteen months after 
the last dose, he presented with a large haematoma on his back 
after a dry needling treatment of the gluteus muscle without other 
complaints. He did not use any medications at the time of presenta-
tion. Physical examination revealed a large haematoma in the lumbar 
region which extended to his right upper leg, which was illustrated 
earlier.2 Laboratory testing revealed an isolated prolonged aPTT of 
62 seconds which did not normalize after mixing with normal pooled 
plasma (54 seconds; Table 1). FVIII:C was strongly reduced (0.02 U/
mL) and a factor VIII inhibitor was present (24.6 BU/mL; Table 1). 
The lymphocyte count was normal (Table 1). A diagnosis of AHA 
was made, and he was treated because of severe bleeding with a 
haemoglobin drop to 10.8 g/dL with FEIBA® 100 U/kg on the first 
day followed by 50 U/kg two times daily for 6 days. He was also 
treated with prednisolone (1 mg/kg/d, ie 90 mg/d) and cyclophos-
phamide (200 mg/d) as immunosuppressive therapy (Figure 1B). 
Complete remission of AHA was achieved after 6 weeks (Figure 1B). 
Cyclophosphamide was stopped 10 weeks after presentation, and 
prednisolone was tapered over a period of 7 months.
AHA is a rare auto-immune disorder caused by autoantibod-
ies directed against factor VIII. It occurs mainly at (very) high age, 
or in young women after pregnancy. It is usually idiopathic (50% 
of cases) but AHA may also be associated with malignancies, au-
to-immune diseases, infections, pregnancy and drugs.3-5 In our pa-
tients, additional investigations, including auto-immune serology 
TA B L E  1   Laboratory results
Parameter Patient 1 Patient 2
Reference 
range
Haemoglobin (g/dL) 10.3 10.8 13.7-17.7
Platelets (x109/L) 391 217 150-400
Leucocytes (x109/L) 15.6 5.8 4-10
Lymphocytes (x109/L) 0.84 0.80 0.50-5.00
B-lymphocytes (x109/L) 0.21 -
T-lymphocytes (x109/L) 0.63 -
CD4/CD8 ratio 3.9 -
aPTT (seconds) 80 62 25-31
PT (seconds) 11.3 13.1 9.5-13-5
aPTT mix (seconds) 46 54 25-31
Factor VIII (U/mL) 0.02 0.02 0.60-1.40
vWF antigen (U/mL) 1.79 2.31 0.60-1.40
vWF activity (U/mL) 1.67 2.94 0.60-1.40
Bethesda VIII (BU/mL) 10 24.6 <0.3
Note: Laboratory testing of the haemostasis parameters at presentation.
Abbreviations: aPTT, activated partial thromboplastin time; PT, 
prothrombin time; vWF, von Willebrand Factor.
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(for systemic lupus erythematosus and rheumatoid arthritis), vi-
rology (of hepatitis B and C, and Epstein Barr virus) and a CT scan 
of the thorax and abdomen, did not reveal any underlying cause 
of AHA in our patients. There was no monoclonal gammopathy, 
white blood cell and platelet counts were normal, nor were there 
other signs of a haematological malignancy. Currently, both pa-
tients (three and one year after presentation) are still in remission 
of AHA after treatment with glucocorticoids and cyclophospha-
mide and no other auto-immune disorders or malignancies have 
occurred.6
In literature, an association between alemtuzumab and AHA has 
been described in four other patients.7-11 The indication for alemtu-
zumab was multiple sclerosis in three cases 7-10 and antineutrophil 
cytoplasmic antibody-associated vasculitis in one case.11 The inter-
val between alemtuzumab therapy and the diagnosis of AHA ranged 
from 11 months9,10 to 5 years.8,11 Depletion of regulatory T cells, 
natural killer and dendritic cells and escape of auto-reactive B cells 
after alemtuzumab therapy have been proposed to contribute to the 
increased susceptibility of secondary autoimmunity.1 Because of the 
lack of another explanation and the remarkable young age of our 
patients, we believe that AHA in our patients was related to the ad-
ministration of alemtuzumab. Therefore, AHA should be considered 
in the differential diagnosis of an alemtuzumab-treated patients pre-
senting with an acquired bleeding disorder.
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F I G U R E  1   The concentrations of factor VIII and inhibitor of factor VIII in the first 6 mo of patient 1 (A) and patient 2 (B). The dashed line 
depicts the lower limit of normal of factor VIII. BU, Bethesda Units
(A) (B)
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